Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mushroom powder may lift mood in thyroid cancer survivors

NCT ID NCT07524777

Symptom relief Sponsor: Ling Zhiqiang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study tests whether a mushroom supplement called Ganoderma lucidum spore powder can reduce depression in women who have had thyroid cancer surgery. Three hundred participants will take either the supplement or a placebo daily for three months. Researchers will measure changes in mood, sleep, and gut bacteria to see if the supplement works through the gut-brain connection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sporoderm-removed Ganoderma lucidum spore powder (a mushroom supplement)
What this could lead to
If it works, this could offer a natural way to improve mood and sleep in thyroid cancer survivors with depression.
What could go wrong
This is an early-stage trial with no prior proof in this group. The supplement may not outperform placebo, and results may not apply to men or other ethnicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Apr 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Outpatients at Zhejiang Cancer Hospital with histologically confirmed papillary thyroid carcinoma (post-surgery) and depressive symptoms (HAMD-24 score ≥ 8, confirmed by a clinical psychologist). * Han Chinese ethnicity. * No history of depression or other psychiatric disorders. * Age 18-80 years. * Female. Exclusion Criteria: * Suffering from other gastrointestinal system diseases. * History of gastrointestinal surgery prior to intervention. * Including those with other concurrent malignancies requiring chemotherapy, radiotherapy, biological therapy, or traditional Chinese medicine treatment. * Received antibiotic treatment or microecological modulators within 3 months prior to intervention. * Acute intestinal obstruction. * Patients who are currently taking antidepressant medication, or those whom the investigators judge require immediate initiation of antidepressant medication treatment. * Organic brain diseases, brain trauma. * History of psychiatric disorders, use of psychoactive substances (e.g., drugs). * Severe liver or kidney dysfunction. * Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression depressive disorder thyroid cancer thyroid gland papillary carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Thyroid cancer

Contacts and locations

Locations

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.